UroGen Pharma
URGN
86 hedge funds and large institutions have $473M invested in UroGen Pharma in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 24 reducing their positions, and 8 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 24
36% more capital invested
Capital invested by funds: $347M → $473M (+$126M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
2% more funds holding
Funds holding: 84 → 86 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less call options, than puts
Call options by funds: $8.04M | Put options by funds: $8.55M
2.09% less ownership
Funds ownership: 69.69% → 67.6% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.48M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$4.2M |
| 3 |
JP Morgan Chase
New York
|
+$3.41M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$3.28M |
| 5 |
WCM
Wildcat Capital Management
New York
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$14M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.47M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$2.94M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.62M |
URGN Hedge Fund Activity: Q4 2019 in Review
86 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2019, worth a combined $473M — up 36% from $347M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new URGN positions and 8 closed out — a net gain of 2 holders — while 40 added to existing stakes and 24 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $4.48M. The largest seller was Clal Insurance, cutting an estimated $14M.
- 86 institutional investors held UroGen Pharma (URGN) as of Q4 2019, up from 84 in Q3 2019.
- Funds reported $473M of UroGen Pharma stock for Q4 2019, up 36% quarter-over-quarter.
- 10 funds opened new UroGen Pharma positions in Q4 2019 and 8 closed out, a net change of +2 holders.
- The largest UroGen Pharma buyer in Q4 2019 was Point72 Asset Management, an estimated $4.48M added.
- The largest UroGen Pharma seller in Q4 2019 was Clal Insurance, an estimated $14M sold.
Based on aggregated 13F filings for Q4 2019.